NCT07097142 2026-04-08
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
Clinical Trials
20 trialsNCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT04624256 2026-03-13
GARUDA
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT00809991 2026-02-18
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT03987386 2025-11-12
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT03570827 2025-09-03
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT01444820 2024-12-04
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT01913717 2023-06-28
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
European Institute of Oncology
Phase NA Unknown
NCT02311049 2022-12-29
Hypofractionated Radiotherapy for Prostate Cancer
University Hospital, Ghent
Phase 2 Completed
NCT01921803 2022-12-22
Hypofraction
University Hospital, Ghent
Phase 2 Completed
NCT04535908 2022-10-03
Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.
Medical University of Graz
Phase NA Terminated
NCT03050060 2022-06-22
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Phase 2 Terminated
NCT01505075 2020-11-24
pHART8
Sunnybrook Health Sciences Centre
Phase 1/2 Unknown
NCT02319239 2020-10-28
ESKO
Tampere University Hospital
Phase NA Completed
NCT01146340 2019-10-04
PHART6
Sunnybrook Health Sciences Centre
Phase 1/2 Completed
NCT02880345 2019-04-23
RADVAXâ„¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT03419130 2018-12-07
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00129025 2011-10-10
Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer
AHS Cancer Control Alberta
Phase 1/2 Completed